• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Endocrinol (Oxf) . Low Serum 25-hydroxyvitamin D (25[OH]D) Levels in Patients Hospitalised With COVID-19 Are Associated With Greater Disease Se

tetano

Editor, Senior Moderator
Clin Endocrinol (Oxf)


. 2020 Jul 3.
doi: 10.1111/cen.14276. Online ahead of print.
Low Serum 25-hydroxyvitamin D (25[OH]D) Levels in Patients Hospitalised With COVID-19 Are Associated With Greater Disease Severity


Grigorios Panagiotou[SUP] 1 [/SUP], Su Ann Tee[SUP] 1 [/SUP], Yasir Ihsan[SUP] 1 [/SUP], Waseem Athar[SUP] 2 [/SUP], Gabriella Marchitelli[SUP] 3 [/SUP], Donna Kelly[SUP] 4 [/SUP], Christopher S Boot[SUP] 5 [/SUP], Nadia Stock[SUP] 3 [/SUP], James Macfarlane[SUP] 2 [/SUP], Adrian R Martineau[SUP] 6 [/SUP], Graham Burns[SUP] 2 [/SUP], Richard Quinton[SUP] 1 7 [/SUP]



Affiliations

Abstract

Objectives: Vitamin D deficiency (VDD) has been proposed to play a role in Coronavirus Disease 2019 (COVID-19) pathophysiology. We aim to evaluate our implementation of a local protocol for treatment of VDD among patients hospitalized for COVID-19; to assess the prevalence of VDD among COVID-19 inpatients, and examine potential associations with disease severity and fatality.
Design and participants: We conducted a retrospective interim audit of a local clinical care pathway for 134 inpatients with COVID-19. Prevalence of VDD, compliance with local treatment protocol and relationship of baseline serum 25(OH)D with markers of COVID-19 severity and fatality were analysed.
Results: 55.8% of eligible patients received Colecalciferol replacement, albeit not all according to the suggested protocol. Patients admitted to ITU were younger than those managed on medical wards (61.1 years ? 11.8 vs. 76.4 years ? 14.9, respectively, p<0.001), with greater prevalence of hypertension, higher baseline respiratory rate, National Early Warning Score-2 and C-Reactive protein level. While mean serum 25(OH)D levels were comparable (p=0.3), only 19% of ITU patients had 25(OH)D levels greater than 50 nmol/L vs. 39.1% of non-ITU patients (p=0.02). However, there was no association with fatality, potentially due to small sample size and prompt diagnosis and treatment of VDD.
Conclusions: Higher prevalence of VDD was observed in patients requiring ITU admission compared to patients managed on medical wards. Larger prospective studies and/or clinical trials are needed to validate and extend our observations.

Keywords: Coronavirus; Covid-19; acute respiratory distress syndrome; colecalciferol; vitamin D
 
Back
Top Bottom